
|Videos|November 9, 2021
A Deep Dive on Tapinarof
Author(s)Mary Scoviak, Managing Editor
In this video interview, Mark Lebwohl, MD, explains why topicals for inflammatory conditions are vital for treatment.
Advertisement
Mark G. Lebwohl, MD, professor of dermatology at Mount Sinai, New York, New York, details how tapinarof cream (GSK2894512; Dermavant), a once-daily topical aryl hydrocarbon receptor (AhR) agonist, is effective for psoriasis, gives his thoughts on the current treatment pipeline, and more in this video interview.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Phase 2 Nemolizumab Trial Opens for CPUO
5


















